Related Experiment Video
Updated: May 9, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Ezetimibe in combination with a statin does not reduce all-cause mortality.
Akshar Y Patel1, Jayasree Pillarisetti, Joshua Marr
1Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Journal of Clinical Medicine Research
|July 19, 2013
Summary
The combination of ezetimibe and statin did not reduce all-cause mortality compared to statin alone in the general population. Higher HDL-C and omega-3 fatty acid use were linked to improved survival.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Clinical Trials
Background:
- Ezetimibe-statin combination lowers LDL cholesterol but its impact on mortality is uncertain.
- Previous trials focused on select groups, leaving general population data on mortality impact unreported.
Purpose of the Study:
- To investigate the effect of ezetimibe-statin combination on all-cause mortality in a general patient population.
- To compare mortality rates between patients on statin monotherapy versus those on a statin-ezetimibe combination.
Main Methods:
- Retrospective analysis of 3,827 patients prescribed statin or statin-ezetimibe from 2005-2008.
- Logistic regression analysis to assess ezetimibe's impact on mortality, controlling for covariates.
- Inclusion of socio-demographic, clinical variables, and mortality records.
Main Results:
- No significant difference in all-cause mortality was observed between the statin-only and statin-ezetimibe groups.
- Hypertension, higher HDL-C, and omega-3 fatty acid use were associated with ezetimibe use.
- After controlling for covariates, the drug combination did not show a mortality benefit.
Conclusions:
- Ezetimibe in combination with statin does not provide a significant mortality benefit over statin monotherapy.
- Higher HDL-C and omega-3 fatty acid intake were associated with a notable survival advantage.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:27Combined Effects of Drugs: Synergism
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:09Hepatic Drug Clearance: Effect of Protein Binding
Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...